Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?

Volume: 41, Issue: 1, Pages: 6 - 10
Published: Jan 1, 2018
Abstract
Two recent observational studies reported a remarkably lower rate of all-cause death associated with sodium-glucose cotransporter 2 inhibitor (-SGLT2i) use in all patients with type 2 diabetes and not only those at increased cardiovascular risk. The >50% lower mortality rates reported in these studies are much greater than those found in the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients...
Paper Details
Title
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Published Date
Jan 1, 2018
Volume
41
Issue
1
Pages
6 - 10
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.